# IPHA catalysts: Innate Pharma SA PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ipha/catalysts

> Innate Pharma SA (IPHA) has 4 upcoming catalysts. The next is the Innate Pharma SA topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IPHA?

Innate Pharma SA (IPHA) has 4 upcoming catalysts. The next is the Innate Pharma SA topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously." [Calendar and source filings](https://sec-api.dev/companies/ipha/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001628280-26-067408, https://www.sec.gov/Archives/edgar/data/1598599/000162828026067408/exhibit991_261027.htm (retrieved 2026-11-12). Last confirmed 2026-10-27. Cite: https://sec-api.dev/companies/ipha/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Innate Pharma SA |
| Ticker | IPHA (Nasdaq) |
| SEC CIK | 1598599 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/ipha |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 13, 2018 | [Lumoxiti (moxetumomab pasudotox-tdfk) FDA approval](https://sec-api.dev/pdufa/moxetumomab-pasudotox-tdfk) | IPHA |  | completed, approved | "BLA761104 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180913, review_priority PRIORITY; sponsor_name INNATE PHARMA; product LUMOXITI (MOXETUMOMAB PASUDOTOX-TDFK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761104%22)) |
| June 26, 2023 | [IPH5201 trial start](https://sec-api.dev/pdufa/iph5201) | IPHA |  | completed | "On June 26, 2023, the Company announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607), sponsored by the Company, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1598599/000159859925000042/inpha-20241231.htm)) |
| March 6, 2024 | [IPH6501 trial start](https://sec-api.dev/pdufa/iph6501) | IPHA | Relapsed and/or Refractory CD20-expressing B-cell non-Hodgkin's lymphoma | completed | "On March 6, 2024, the Company announced that the first patient was dosed in its Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell non-Hodgkin's lymphoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1598599/000159859925000042/inpha-20241231.htm)) |
| Jun 2024 | [IPH6501 trial start](https://sec-api.dev/pdufa/iph6501) | IPHA |  | completed | "The €0.4 million increase in expenses related to the IPH6501 program reflects the advancement of clinical activities; as a reminder, this program entered clinical development after the first patient was dosed in June 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026021168/a200326exhibit991.htm)) |
| Jan 2025 | [IPH5201 trial start](https://sec-api.dev/pdufa/iph5201) | IPHA |  | completed | "This decrease in clinical programs expenses mainly results from (i) a €6.3 million decrease in expenses related to the IPH4502 program, following the reduction in CMC and toxicology activities, partially offset by higher costs associated with the progressive start-up of clinical activities; as a reminder, this program entered clinical development after the first patient was dosed in January 2025; (ii) a €0.7 million decrease in expenses related to the IPH5201 (anti-CD39) program; (iii) a € 0.5 million decrease in expenses related to the lacutamab program, whose Phase 2 clinical study is in the process of being closed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026021168/a200326exhibit991.htm)) |
| Q1 2025 | [IPH4502 trial start](https://sec-api.dev/pdufa/iph4502) | IPHA |  | scheduled | "Innate expects to initiate the Phase 1 study by Q1 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000159859924000086/exhibit991-241113.htm)) |
| January 27, 2025 | [IPH4502 trial start](https://sec-api.dev/pdufa/iph4502) | IPHA | advanced solid tumors known to express Nectin-4 | completed | "•On January 27, 2025, the Company announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000159859925000075/inpha-20250630_d2.htm)) |
| January 8, 2026 | [Lacutamab primary completion](https://sec-api.dev/pdufa/lacutamab) | IPHA | Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides/Sezary Syndrome | completed | "NCT03902184 (IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-08 (ACTUAL); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03902184)) |
| 2H 2026 | [Innate Pharma SA topline data readout](https://sec-api.dev/companies/ipha/catalysts) | IPHA |  | scheduled | "Enrollment in the trial is complete, and data readout is expected in H2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026062360/exhibit991-260917.htm)) |
| late 2026 | [IPH4502 interim data readout](https://sec-api.dev/pdufa/iph4502) | IPHA |  | scheduled | "•Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000159859926000008/a260721exhibit991.htm)) |
| late 2026 | [IPH4502 topline data readout](https://sec-api.dev/pdufa/iph4502) | IPHA |  | scheduled | "Looking ahead, we will present Phase 1 data from IPH4502 at ENA 2026 and expect the PACIFIC-9 Phase 3 readout for monalizumab by year-end, as we remain focused on delivering value for patients and shareholders."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026062360/exhibit991-260917.htm)) |
| 1H 2027 | [Innate Pharma SA topline data readout](https://sec-api.dev/companies/ipha/catalysts) | IPHA |  | scheduled | "Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026067408/exhibit991_261027.htm)) |
| Q1 2027 | [Lacutamab trial start](https://sec-api.dev/pdufa/lacutamab) | IPHA |  | scheduled | "Transaction closing triggers the USD 75 million upfront payment and marks the initiation of the TELLOMAK-3 confirmatory Phase 3 study, with first patient expected in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598599/000162828026062357/exhibit991-260916.htm)) |
| June 2027 | [Iph5201 + durvalumab + standard chemotherapy primary completion](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) | IPHA | Non Small Cell Lung Cancer | scheduled | "NCT05742607 (IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742607)) |
| Jun to Sep 2027 | [Iph5201 + durvalumab + standard chemotherapy topline data readout](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) | IPHA | Non Small Cell Lung Cancer | scheduled | "NCT05742607 (IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742607)) |

## Drugs

- [IPH4502](https://sec-api.dev/pdufa/iph4502): advanced solid tumors known to express nectin-4
- [IPH5201](https://sec-api.dev/pdufa/iph5201): 
- [Iph5201 + durvalumab + standard chemotherapy](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy): Non Small Cell Lung Cancer
- [IPH6501](https://sec-api.dev/pdufa/iph6501): relapsed and/or refractory cd20-expressing b-cell non-hodgkin's lymphoma
- [Lacutamab](https://sec-api.dev/pdufa/lacutamab): Lymphoma, T-Cell
- [Lumoxiti (moxetumomab pasudotox-tdfk)](https://sec-api.dev/pdufa/moxetumomab-pasudotox-tdfk): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ipha/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IPHA catalysts: Innate Pharma SA PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ipha/catalysts

```bibtex
@misc{secapidev_companies_ipha_catalysts_20261116,
  title        = {IPHA catalysts: Innate Pharma SA PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ipha/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ipha_catalysts_20261116","title":"IPHA catalysts: Innate Pharma SA PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ipha/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
